Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed · Phase 3

Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with chemotherapy may reduce resistance to the drug, and allow more tumor cells to be killed. It is not yet known whether combination chemotherapy plus PSC 833 is more effective than combination chemotherapy alone in treating patients with relapsed or refractory multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without PSC 833 in treating patients with relapsed or refractory multiple myeloma.

Key facts

Study ID

NCT00002878

Run by

Eastern Cooperative Oncology Group

Starts

1997-06-30

Last updated by the study team

2023-06-15

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California San Diego Cancer Center — La Jolla, California, United States
• UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
• CCOP - Christiana Care Health Services — Wilmington, Delaware, United States
• Walter Reed Army Medical Center — Washington D.C., District of Columbia, United States
• CCOP - Mount Sinai Medical Center — Miami Beach, Florida, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Holden Comprehensive Cancer Center at The University of Iowa — Iowa City, Iowa, United States
• Marlene & Stewart Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• University of Massachusetts Memorial Medical Center — Worcester, Massachusetts, United States
• University of Minnesota Cancer Center — Minneapolis, Minnesota, United States
• Ellis Fischel Cancer Center - Columbia — Columbia, Missouri, United States
• Barnes-Jewish Hospital — St Louis, Missouri, United States
• University of Nebraska Medical Center — Omaha, Nebraska, United States
• CCOP - Southern Nevada Cancer Research Foundation — Las Vegas, Nevada, United States
• Norris Cotton Cancer Center — Lebanon, New Hampshire, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• CCOP - North Shore University Hospital — Manhasset, New York, United States
• Schneider Children's Hospital at North Shore — Manhasset, New York, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• New York Presbyterian Hospital - Cornell Campus — New York, New York, United States
• Mount Sinai Medical Center, NY — New York, New York, United States
• State University of New York - Upstate Medical University — Syracuse, New York, United States
• CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C. — Syracuse, New York, United States
• Lineberger Comprehensive Cancer Center, UNC — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.